- Home
- TEI vs FHTX Comparison
TEI vs FHTX Comparison
Compare TEI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | FHTX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.9M | 323.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TEI | FHTX |
|---|---|---|
| Price | $6.26 | $3.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 134.0K | 102.8K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $5.44 | $3.27 |
| 52 Week High | $7.00 | $6.95 |
Technical Indicators
Market Signals| Indicator | TEI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 29.09 |
| Support Level | $6.19 | $3.65 |
| Resistance Level | $6.48 | $5.82 |
| Average True Range (ATR) | 0.14 | 0.27 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 23.61 | 2.68 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.